Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases

AUTOR(ES)

Waldmann, Thomas A

FONTE

BioMed Central

RESUMO

Interleukin (IL)-15 is a dangerous inflammatory cytokine that induces tumor-necrosis factor-α, IL-1β and inflammatory chemokines. It inhibits self-tolerance mediated by IL-2 mediated activation-induced cell death and facilitates maintenance of CD8+ memory T-cell survival including that of self-directed memory cells. Disordered IL-15 expression has been reported in patients with an array of inflammatory autoimmune diseases. A series of therapeutic agents that inhibit IL-15 action have been introduced, including the soluble IL-15 receptor (IL-15R) α chain, mutant IL-15, and antibodies directed against the IL-15 cytokine and against the IL-2R/IL-15R β subunit used by IL-2 and IL-15.

Documentos Relacionados

• The current status of targeting BAFF/BLyS for autoimmune diseases
• Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.
• The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases
• Interleukin 1 receptor blockade attenuates the host inflammatory response.
• Local nitric oxide production in viral and autoimmune diseases of the central nervous system.